An Overview of AbbVie’s Diverse Neuropsychiatry Pipeline

• Reviewing AbbVie’s abundant pipeline spanning a range of assets in mood disorders
• Highlighting AbbVie’s priorities and commitment to advancing treatments in MDD, BPD and Schizophrenia
• General overview of programs in Neurology, Neurodegeneration, Migraine and Pain

Speakers:

Chris Ocampo

Head of Psychiatry, Neuroscience Clinical Development

Abbvie